Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation.
Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 266.30% from the stock’s current price. Separately, Wedbush reissued […]
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024